Aimee Usera currently leads drug discovery at Delphia Therapeutics, a leading biotech focused on activation lethality. Aimee has broad experience in medicinal chemistry and drug discovery spanning disease areas and therapeutic modalities, with a focus in oncology. Within Delphia, Aimee is working with the team to bring this new approach of oncology therapeutics to patients.

Aimee’s previous industry experience includes leadership across several projects and portfolios within Global Discovery Chemistry at Novartis Biomedical Research. During her time at Novartis, Aimee discovered novel chemical entities and established new technologies to advance programs through preclinical development. Aimee also led the global Targeted Protein Degradation initiative, driving a portfolio of projects across disease areas from target discovery to the clinic. Prior to joining Delphia, Aimee also served in a leadership role as VP of chemistry at Odyssey Therapeutics.

Aimee holds a Bachelor of Arts in chemistry from College of the Holy Cross and a Ph.D. in chemistry from Johns Hopkins University. Aimee continued her studies as an NIH postdoctoral fellow at MIT.